LOPRESSOR
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Mar 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
LOPRESSOR by Novartis is 12. Approved for the treatment of hemodynamically stable adult patients with myocardial infarction, to reduce the risk of cardiovascular mortality, the treatment of hemodynamically stable adult patients with myocardial infarction (mi) to reduce cardiovascular mortality. First approved in 1984.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LOPRESSOR (metoprolol) is a beta-1 selective adrenergic receptor blocking agent indicated for reducing cardiovascular mortality in hemodynamically stable acute myocardial infarction patients. It works by selectively inhibiting beta-1 adrenergic receptors in the heart, reducing heart rate, cardiac output, and blood pressure.
LOE Approaching
Product approaching loss of exclusivity with no current market share data available; team size likely optimized for maintenance rather than growth.
Mechanism of Action
12.1 Mechanism of Action Metoprolol is a beta 1 -selective (cardioselective) adrenergic receptor blocking agent. This preferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits beta 2 -adrenoreceptors, chiefly located in the bronchial and vascular…
Worked on LOPRESSOR at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.